Company overview
Basic information
Company name
Wellgem Biopharma, UAB
Company code
305953703
VAT code
LT100014725817
Registered address
Kaunas, Viešios g. 13B, LT-44105
Registration date
2021-12-13
Company age: 4 y. 10 mo.
Contact information
Edit data
Phone
Presented as an image – cannot be copied
Presented as an image – cannot be copied
Email
Presented as an image – cannot be copied
Presented as an image – cannot be copied
Website
https://www.wellgem.com
Indicators
Risk factors
Activity
Legal form
Private Limited Liability Company
NACE activity
Other research and experimental development on natural sciences and engineering
Ownership form
Private without foreign capital
UAB Wellgem Biopharma
Company code: 305953703
Address: Kaunas, Viešios g. 13B, LT-44105
VAT code: LT100014725817
Description
This description was generated by artificial intelligence.
Wellgem Biopharma, UAB (company code 305953703) is an operational private limited liability company registered in 2021. It is classified as a private, privately owned Lithuanian non-financial company with a CEO-only governance structure and is listed as a small company. The company is based in Kaunas, at Viešios g. 13B, Kauno m. sav., Kauno apskr. Its main activity is N.72.10.90, research and experimental development on other natural sciences and engineering.
In financial year 2025, the company generated revenue of €243.3K, up 76.8% year on year after a lower 2024 result, but it still reported a net loss of €1.04M. Equity turned positive to €1.21M at the end of 2025, while liabilities reached €8.50M and total assets €9.67M. The company’s profit margin remained negative, reflecting losses that were substantially larger than revenue.
Staffing increased from 6 average employees in 2023 to 20 in 2025, before easing to 17 so far in 2026. The average monthly wage was €4,298.05 in 2025 and €3,403.67 so far in 2026. Estimated annual payroll for the latest staff year is €694.3K.
In financial year 2025, the company generated revenue of €243.3K, up 76.8% year on year after a lower 2024 result, but it still reported a net loss of €1.04M. Equity turned positive to €1.21M at the end of 2025, while liabilities reached €8.50M and total assets €9.67M. The company’s profit margin remained negative, reflecting losses that were substantially larger than revenue.
Staffing increased from 6 average employees in 2023 to 20 in 2025, before easing to 17 so far in 2026. The average monthly wage was €4,298.05 in 2025 and €3,403.67 so far in 2026. Estimated annual payroll for the latest staff year is €694.3K.
Download a detailed company report
Make confident decisions with all the information about Wellgem Biopharma, UAB. In one document, you will find full financial data, risk and potential assessment, and key Scoris insights.